[HTML][HTML] Baricitinib versus placebo or adalimumab in rheumatoid arthritis
…, J Reyes Gonzaga, S Yakushin, T Ishii… - … England Journal of …, 2017 - Mass Medical Soc
Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that
may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted a …
may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted a …
Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment
…, CL Dickson, JR Camp, TE Cardillo, T Ishii… - The Journal of …, 2019 - jrheum.org
Objective. Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for
adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib’s …
adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib’s …
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular …
H Saeki, H Nakagawa, K Nakajo, T Ishii… - The Journal of …, 2017 - Wiley Online Library
Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques,
affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to …
affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to …
RANKL‐induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis
We showed that CD9, a member of tetraspanin superfamily proteins, is expressed in a
specific membrane microdomain, called “lipid raft,” and is crucial for cell fusion during …
specific membrane microdomain, called “lipid raft,” and is crucial for cell fusion during …
Enhanced local production of osteopontin in rheumatoid joints.
…, N Yamaguchi, K Nishioka, T Mima, T Ishii… - The Journal of …, 2002 - jrheum.org
OBJECTIVE: To investigate the involvement of osteopontin (OPN) in the pathogenesis of
rheumatoid arthritis (RA), localization and production of OPN were examined in patients with RA…
rheumatoid arthritis (RA), localization and production of OPN were examined in patients with RA…
Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients
T Ishii, H Onda, A Tanigawa, S Ohshima… - DNA …, 2005 - academic.oup.com
We have identified the genes whose expressions are augmented in the blood cells of the
patients with systemic lupus erythematosus (SLE) using the ‘stepwise subtraction’ technique …
patients with systemic lupus erythematosus (SLE) using the ‘stepwise subtraction’ technique …
[HTML][HTML] Cell Cycle-Dependent Rho GTPase Activity Dynamically Regulates Cancer Cell Motility and Invasion In Vivo
The mechanism behind the spatiotemporal control of cancer cell dynamics and its possible
association with cell proliferation has not been well established. By exploiting the intravital …
association with cell proliferation has not been well established. By exploiting the intravital …
[HTML][HTML] Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough
S Sato, J Saito, Y Sato, T Ishii, W Xintao, Y Tanino… - Respiratory …, 2008 - Elsevier
BACKGROUND: Prolonged cough is one of the troublesome symptoms commonly seen in
daily practice. Especially, detection of allergic cough such as bronchial asthma (BA), cough …
daily practice. Especially, detection of allergic cough such as bronchial asthma (BA), cough …
Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications
YT Saeki Mima, T Ishii, A Ogata… - British journal of …, 2003 - Wiley Online Library
In this study, we examined osteopontin (OPN) production in myeloma cells and plasma OPN
levels in multiple myeloma (MM) patients. We assessed OPN production in bone marrow …
levels in multiple myeloma (MM) patients. We assessed OPN production in bone marrow …
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 …
…, M Issa, Y Isaka, N Akashi, T Ishii… - Modern …, 2020 - academic.oup.com
Objectives: Baricitinib is a selective oral inhibitor of JAK1/JAK2 for patients with moderately-to-severely
active rheumatoid arthritis (RA). Baricitinib’s safety profile in Japanese patients …
active rheumatoid arthritis (RA). Baricitinib’s safety profile in Japanese patients …